Viemed Healthcare walked into its Q1 2026 earnings print carrying a 3.5% weekly loss and walked out with a 2.3% bounce — a tidy illustration of how much was already priced for caution before the numbers dropped.
Q1 results split neatly between a revenue beat and an earnings miss. Sales came in at $75.4 million, up 28% year-over-year and ahead of the $74.4 million consensus. EPS of $0.06 missed the $0.09 estimate by a third. The shortfall traced mainly to ventilator compliance headwinds: new NCD criteria have pushed turnover rates higher on recently enrolled patients, compressing the net census to 12,089 even as new patient starts accelerated — 759 ventilator setups in March alone, against 692 a year ago. Management framed this as a structural transition, not a demand problem. The market, for now, appears to be giving them the benefit of the doubt. Full-year revenue guidance was trimmed to a tighter range of $312–$320 million from the prior $310–$320 million, nudging the lower bound up — a modest but deliberate signal of confidence heading into Q2.
The short-positioning picture adds little pressure here. Short interest at 1.1% of free float is essentially immaterial, and a 7.7% week-on-week increase in shares short is barely worth noting at this absolute level. Cost to borrow has crept higher over the week — up roughly 27% to 0.47% — though it remains near its recent lows and is well below the spikes above 1.0% seen in mid-April. Borrow availability is extremely loose, with the lending market nowhere near saturation. Options positioning reflects the same low-conviction picture: the put/call ratio of 0.02 sits near the floor of its 52-week range, meaning traders are overwhelmingly positioned via calls rather than protective puts. The ORTEX short score of 29.5, in the 77th percentile by rank, is the one notable outlier — elevated relative to the stock's modest short float, suggesting the algorithmic signal is picking up some near-term tension between positioning and price momentum.
The institutional ownership register is notably concentrated at the top. BlackRock holds roughly 12% of shares outstanding, with Vanguard at 4.6% and company President Michael Moore at a closely-watched 4.6% — though Moore trimmed roughly 137,000 shares across three days in mid-March at prices between $8.77 and $9.42, raising over $1.2 million. Those sales now look well-timed given the stock sat near $9.70 as of Tuesday. The CFO and other executives also sold modest quantities in January alongside restricted stock awards, a routine pattern. Net insider flows over the 90-day window lean net-positive in share terms — largely the effect of awards — but the open-market direction from the President is worth tracking.
Analyst coverage is thin and dated. Two buy recommendations carry a mean price target of $13.00, implying 34% upside from current levels — but the most recent analyst data in the ORTEX system is from March 2026, and the only tracked recent change (an RBC Capital target cut to $9.00 from $13.00 from late 2021) reflects a very different environment. Given the stale coverage picture, the $13 target should be treated as context rather than current conviction. Valuation at roughly 4.5x EV/EBITDA and a PE near 14x keeps the stock cheap relative to larger health services peers, which may explain why the buy recommendation count hasn't shifted despite a tough earnings reaction last quarter — when the stock fell 3.3% on the day after the Q4 print in early March.
With the Q1 call now behind it and the next print pencilled for August 5, the key watch for VMD is the trajectory of the ventilator census: whether the new NCD compliance curve stabilises and net patient counts begin recovering will determine whether the growth story built on sleep and maternal health expansion can also reclaim its respiratory services engine.
See the live data behind this article on ORTEX.
Open VMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
